What are AstraZeneca's strengths?

The company has blockbuster drugs like Tagrisso, Imfinzi, and Farxiga, strong oncology growth, and a pipeline of over 100 projects.

Should I buy AstraZeneca stock now?

It depends on investor goals. The recent setback is temporary, but fundamentals are strong. Monitor pipeline developments.

AstraZeneca Stock Down 7% in 3 Months: Buy, Sell or Hold?

AstraZeneca (AZN) shares declined 7% in 3 months following a setback with its camizestrant drug. Despite this, the company's strong portfolio of blockbuster drugs, growth in oncology, and robust pipeline support its long-term outlook.

June 16, 2026

2 min read

Source: Zacks

Key Numbers

stock decline percent

time period

3 months

AstraZeneca (AZN) shares have fallen 7% over the past three months after a setback in the clinical trial of camizestrant, an experimental breast cancer drug. However, the company continues to boast a strong portfolio of blockbuster drugs, growth in its oncology segment, and a deep pipeline that supports its long-term targets.

Details of the Decline

AstraZeneca reported disappointing results from trials of camizestrant, a drug for advanced breast cancer. This triggered a sell-off that pushed the stock down 7% in three months.

Key Strengths

Blockbuster Drugs: Drugs like Tagrisso, Imfinzi, and Farxiga generate substantial revenue.
Oncology Growth: The oncology segment is a key growth driver, with several late-stage new treatments.
Pipeline: AstraZeneca has over 100 projects in various stages of development, offering future opportunities.

What This Means for Investors

Despite the recent setback, the company's strong fundamentals support long-term growth. Investors should monitor developments in camizestrant trials and the overall pipeline, while considering the current valuation of the stock.

Frequently Asked Questions

The stock fell 7% in 3 months due to a setback in the camizestrant breast cancer drug trial.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.